An evidence-based comparison of two GLP-1 medicines reshaping diabetes and obesity care
| Key TakeawaysTirzepatide is a dual GIP and GLP-1 receptor agonist (sold as Mounjaro), while Ozempic is semaglutide, a single GLP-1 receptor agonist.In the head-to-head SURMOUNT-5 trial, tirzepatide produced average weight loss of 20.2% versus 13.7% with semaglutide at 72 weeks.Both are CDSCO-approved in India and prescription-only. Choice depends on diagnosis, tolerability, dosing comfort and your endocrinologist’s assessment. |
If you are weighing tirzepatide against Ozempic for type 2 diabetes or weight management, the right answer depends on more than the headline numbers.
This guide breaks down how the two medicines compare on mechanism, weight loss, blood sugar control, side effects, dosing and India access, so you can have a more informed conversation with your doctor.
1. Are tirzepatide and Ozempic the same drug?
No, they are different molecules in the same broader family of incretin-based medicines.
Ozempic is a brand of semaglutide, a once-weekly injection that activates a single hormone receptor known as GLP-1 (glucagon-like peptide-1).
Tirzepatide is sold in India as Mounjaro, and it is a dual agonist: it activates both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide).
This pharmacological difference matters. Mechanistic work published in JCI Insight describes tirzepatide as an imbalanced and biased dual agonist, with stronger engagement of the GIP receptor than the GLP-1 receptor.
A review in Frontiers in Endocrinology reports that activating both receptors together produced a stronger cellular signal in a human pancreatic beta-cell line than either GIP or GLP-1 alone, which may help explain the larger metabolic effects seen in clinical trials.
Note also that semaglutide is sold under three brand names: Ozempic (injection for type 2 diabetes), Wegovy (injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes).
Tirzepatide is sold as Mounjaro in India and as Zepbound in some other markets for obesity.
How the two drugs work
| Feature | Tirzepatide (Mounjaro) | Semaglutide (Ozempic / Wegovy / Rybelsus) |
|---|---|---|
| Drug class | Dual GIP + GLP-1 receptor agonist | Single GLP-1 receptor agonist |
| Receptors activated | Two: GIP and GLP-1 | One: GLP-1 |
| How it lowers appetite | Slows gastric emptying, acts on appetite centres in the brain, and adds GIP signalling | Slows gastric emptying and acts on appetite centres in the brain |
| How it lowers blood sugar | Glucose-dependent insulin release plus suppressed glucagon, with added GIP-mediated insulin sensitisation | Glucose-dependent insulin release plus suppressed glucagon |
| Manufacturer | Eli Lilly | Novo Nordisk |
2. Which one causes more weight loss?
In direct head-to-head comparison, tirzepatide produced more weight loss than semaglutide, but both are substantially more effective than older weight loss medicines.
The most rigorous evidence comes from the SURMOUNT-5 trial, a 72-week, randomised, open-label, phase 3b study of 751 adults living with obesity or overweight plus a weight-related condition (but without type 2 diabetes).
Results were published in The New England Journal of Medicine in May 2025.
At 72 weeks, average body weight reduction was 20.2% with tirzepatide compared with 13.7% with semaglutide.
In absolute terms, this translated to roughly 22.8 kg of weight loss for tirzepatide and 15.0 kg for semaglutide.
The American College of Cardiology summary of the trial also notes a larger reduction in waist circumference with tirzepatide (18.4 cm versus 13.0 cm).
On secondary endpoints, 31.6% of tirzepatide users hit at least a 25% body weight reduction, versus 16.1% of semaglutide users. These are the kind of outcomes that older obesity medicines have not been able to match.
Trial context matters too. The earlier SURMOUNT-1 study in NEJM tested tirzepatide alone against placebo in 2,539 adults and found average weight loss of 16.0% (5 mg), 21.4% (10 mg) and 22.5% (15 mg) over 72 weeks.
For semaglutide, the comparable STEP-1 trial in adults with obesity reported about 14.9% mean weight loss.
A three-year follow-up of SURMOUNT-1 treatment-adherent participants, published in NEJM in 2025, suggests weight loss can be sustained with continued treatment: roughly two thirds of adherent participants had regained 5% or less of their lowest weight three years after starting tirzepatide.
Head-to-head and key landmark trial results
| Trial (year) | Comparison | Average weight loss | Duration |
|---|---|---|---|
| SURMOUNT-5 (2025) | Tirzepatide vs. semaglutide | 20.2% vs. 13.7% | 72 weeks |
| SURMOUNT-1 (2022) | Tirzepatide 15 mg vs. placebo | 22.5% vs. 2.4% | 72 weeks |
| STEP-1 (2021) | Semaglutide 2.4 mg vs. placebo | 14.9% vs. 2.4% | 68 weeks |
| SURPASS-2 (2021, T2D) | Tirzepatide 15 mg vs. semaglutide 1 mg | 11.2 kg vs. 5.7 kg | 40 weeks |
Important caveat: these are average results from controlled trials. Individual response varies, and weight loss with both drugs tends to plateau once the medicine is stopped.
Decisions about starting, dose escalation or switching should always involve a qualified endocrinologist or obesity-medicine specialist.
3. Which one is better for type 2 diabetes control?
For type 2 diabetes specifically, the comparison comes from SURPASS-2, a 40-week head-to-head trial of 1,879 adults with type 2 diabetes inadequately controlled on metformin. Results were published in NEJM in 2021.
All three doses of tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg, which is the highest approved type 2 diabetes dose for the injectable form.
Tirzepatide doses dropped HbA1c by 2.01% (5 mg), 2.24% (10 mg) and 2.30% (15 mg), versus 1.86% with semaglutide.
Weight loss in this diabetes population was also greater with tirzepatide, with the 15 mg dose producing about 11.2 kg of mean weight loss against 5.7 kg for semaglutide 1 mg.
Notably, 60% of the tirzepatide 15 mg group reached HbA1c of 6.5% or lower combined with weight loss of 10% or more, without clinically significant hypoglycaemia.
A practical point for Indian patients: type 2 diabetes is common, with the ICMR-INDIAB national study published in The Lancet Diabetes & Endocrinology estimating that 101 million Indians live with diabetes and another 136 million are pre-diabetic.
Both medicines have a role in modern type 2 diabetes care, though current Indian prescribing patterns and access vary.
4. How do their side effects compare?
Both medicines share a similar side-effect profile, dominated by gastrointestinal symptoms that are usually mild to moderate and most common during dose escalation.
A meta-analysis published in Cureus / PubMed Central pooled six randomised trials with 4,586 patients on tirzepatide. The incidence of nausea was around 20.4% in tirzepatide groups versus 10.5% in comparators, and vomiting was 9.1% versus 4.9%.
A separate Bayesian network meta-analysis of GLP-1 medicines found that semaglutide carried a higher risk of diarrhoea than other GLP-1 drugs, while tirzepatide carried the highest risk of nausea and diarrhoea within the class.
Discontinuation rates due to side effects are broadly comparable. In SURMOUNT-5, 2.7% of tirzepatide users discontinued due to gastrointestinal side effects, against 5.6% with semaglutide.
Both drugs carry the same boxed warning in their FDA labels for thyroid C-cell tumours (seen in rodent studies). They should not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Common and important side effects
| Side effect | Tirzepatide | Semaglutide | Note |
|---|---|---|---|
| Nausea | ~20% | ~15–20% | Most common in first 8–12 weeks |
| Vomiting | ~9% | ~5–9% | Reduces with slow dose escalation |
| Diarrhoea / constipation | Common | Common (slightly higher diarrhoea) | Hydration and fibre help |
| Hypoglycaemia | Low risk alone, higher with insulin or sulphonylurea | Low risk alone, higher with insulin or sulphonylurea | Doses of other agents may need review |
| Pancreatitis | Rare, reported | Rare, reported | Stop and seek care for severe abdominal pain |
| Gallbladder issues | Reported | Reported | Linked to rapid weight loss in general |
| Thyroid C-cell tumour signal | Boxed warning (rodent data) | Boxed warning (rodent data) | Avoid with personal or family history of MTC or MEN 2 |
If gastrointestinal effects are intolerable, slowing the dose escalation, taking the injection in the evening, and adjusting meal size are commonly used strategies.
These should be discussed with the prescribing doctor rather than self-managed.
5. How are they dosed and administered?
Both medicines are once-weekly subcutaneous injections, taken on the same day each week and given in the abdomen, thigh or upper arm.
They follow a gradual dose-escalation schedule designed to limit nausea and other gastrointestinal symptoms.
Tirzepatide (Mounjaro) in India is available in single-dose vials and as a KwikPen multi-dose prefilled pen with six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.
This is detailed in the Eli Lilly India announcement and in regulatory reporting by Business Standard.
Ozempic in India is supplied in prefilled pens with weekly doses of 0.25 mg, 0.5 mg, 1 mg and, in some markets, 2 mg. The CDSCO cleared Ozempic for type 2 diabetes in September 2025, as reported by Business Today. Wegovy and the oral tablet form Rybelsus are also approved in India for their respective indications.
Dose escalation comparison
| Stage | Tirzepatide (Mounjaro) | Semaglutide (Ozempic for T2D) | Semaglutide (Wegovy for weight) |
|---|---|---|---|
| Starting dose | 2.5 mg weekly for 4 weeks | 0.25 mg weekly for 4 weeks | 0.25 mg weekly for 4 weeks |
| Step 2 | 5 mg weekly | 0.5 mg weekly | 0.5 mg weekly |
| Step 3 | 7.5 mg, then 10 mg weekly | 1 mg weekly | 1 mg, then 1.7 mg weekly |
| Maximum dose | 15 mg weekly | 2 mg weekly (where approved) | 2.4 mg weekly |
| Escalation pace | Increase by 2.5 mg every 4 weeks | Increase every 4 weeks | Increase every 4 weeks |
| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
Both drugs require cold-chain storage (typically 2–8°C until in use), which can be a practical consideration if you travel within India during summer months.
6. What does availability look like in India?
Both medicines are now CDSCO-approved and commercially available, but the access map looks different for each.
Eli Lilly launched Mounjaro (tirzepatide) in India in March 2025, initially in vial format and then in the KwikPen multi-dose pen format from mid-2025, with all six dose strengths (2.5 mg to 15 mg) covered.
The launch was reported by the DD News Bureau and the regulatory update for the KwikPen format by the Eli Lilly press release.
Mounjaro is approved in India both for type 2 diabetes and for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition.
Novo Nordisk’s Ozempic received CDSCO marketing authorisation in September 2025, with a formal Indian launch in December 2025. As reported by Business Today, Ozempic is indicated in India for type 2 diabetes, not for primary obesity treatment. For weight management, Novo Nordisk markets Wegovy (injectable semaglutide 2.4 mg) and Rybelsus (oral semaglutide tablet).
In January 2026, Business Standard reported the first wave of CDSCO approvals for generic semaglutide formulations (covering Sun Pharma, Zydus Lifesciences, Alkem Laboratories and Dr Reddy’s Laboratories), tied to upcoming patent expiry in India.
This is likely to expand access to semaglutide products through 2026, though commercial launches and brand availability vary.
Both medicines are prescription-only in India and should be initiated and monitored by an endocrinologist or other qualified physician. Cold-chain logistics mean availability is currently strongest in larger cities and through major pharmacy chains and hospital pharmacies.
7. Which one might be right for you?
The right medicine depends on your diagnosis, treatment history, tolerability, dosing comfort and your doctor’s clinical assessment.
Some practical patterns from the trial data and approved indications:
- For type 2 diabetes: both are options and both are typically used after metformin. Tirzepatide showed greater HbA1c and weight reductions in SURPASS-2, but semaglutide has a longer track record.
- For obesity or overweight with comorbidities: tirzepatide (Mounjaro) is currently the only dual-agonist option approved in India for chronic weight management. Wegovy (semaglutide 2.4 mg) is the semaglutide-class option.
- If you cannot tolerate injections: oral semaglutide (Rybelsus) is currently the only oral GLP-1 option, although it is approved for type 2 diabetes rather than primary weight loss in many regions.
- If you have a personal or family history of medullary thyroid carcinoma or MEN 2: neither tirzepatide nor semaglutide is suitable.
- If you are pregnant, planning pregnancy or breastfeeding: both medicines should be avoided. Speak with a doctor about safer options.
Both drugs are intended as a complement to nutrition and physical activity, not a replacement. Weight loss often plateaus and can reverse if the medicine is stopped, which is why long-term planning with a clinician matters more than the short-term comparison.
| Bottom LineTirzepatide and Ozempic are both effective once-weekly injections, but they are not the same drug. In direct comparison, tirzepatide produced greater weight loss and HbA1c reductions, while side effects are broadly similar. Both are CDSCO-approved and prescription-only in India. The right choice is the one your doctor recommends after weighing your medical history, goals and tolerance, not the one with the louder headline. |
Frequently Asked Questions
Which causes more weight loss, tirzepatide or Ozempic?
In the head-to-head SURMOUNT-5 trial published in NEJM in 2025, tirzepatide produced 20.2% average weight loss over 72 weeks compared with 13.7% with semaglutide (the molecule in Ozempic and Wegovy).
Individual response varies, and decisions about which medicine to use should be based on a full clinical assessment with an endocrinologist.
Which drug is better for type 2 diabetes, tirzepatide or semaglutide?
In the SURPASS-2 head-to-head trial, all three doses of tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg.
Tirzepatide 15 mg lowered HbA1c by 2.30% versus 1.86% with semaglutide. Both medicines are legitimate options for type 2 diabetes; your endocrinologist will choose based on your overall profile.
Can I switch from Ozempic to Mounjaro for better results?
Switching between these medicines is an individualised clinical decision and should only be done under the supervision of an endocrinologist.
Factors such as your current dose, side-effect history, blood sugar control and indication (diabetes versus weight management) all matter. Do not switch on your own.
Are tirzepatide and Ozempic the same as Wegovy and Rybelsus?
No. Ozempic (injection, type 2 diabetes), Wegovy (injection, chronic weight management) and Rybelsus (oral tablet, type 2 diabetes) all contain semaglutide.
Tirzepatide is a different molecule sold in India as Mounjaro. The brand depends on the indication and formulation.
Are these drugs safe long-term for Indian patients?
Long-term safety data out to three years exists for tirzepatide (SURMOUNT-1 extension) and longer for semaglutide.
Indian patients should be aware that both drugs were tested in largely non-Indian populations, and side effects, dose responses and adherence patterns can vary individually. Always work with a qualified clinician for any GLP-1 therapy.
Medical disclaimer: This article is for general information only and does not replace medical advice, diagnosis or treatment from a qualified clinician. Both tirzepatide and semaglutide are prescription-only medicines. Do not start, stop, change doses or switch between these medicines without supervision from a qualified endocrinologist or your treating physician.
